Imaging Study of Changes in 18FF-AraG Uptake During Anti-PD-1 Therapy in Advanced Non-small Cell Lung Cancer

What this Trial Is About

Researchers are investigating changes in the uptake of a special imaging tracer called 18FF-AraG to better understand how activated T-cells behave during anti-PD-1 immunotherapy in patients with advanced non-small cell lung cancer NSCLC. This study aims to improve the assessment of the tumor microenvironment by using PET scans to detect immune activity, helping to identify areas in tumors with high concentrations of activated T-cells. Participants in this trial will receive three 18FF-AraG PET scans at the start of treatment, at two weeks, and at six weeks during anti-PD-1 immunotherapy. These scans are used to measure the amount of activated T-cells in tumor lesions and lymphoid organs over time, providing valuable information about the immune response to treatment. During the study, researchers will evaluate changes in tracer uptake and correlate these with tumor response at twelve weeks. Participants will provide either a fresh or archival biopsy, and their health status will be monitored through imaging and clinical assessments. The study will continue through twelve weeks to assess immune activity and treatment effects, with safety and performance status monitored throughout the trial period.

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer